On May 16, 2022 ​Imago BioSciences, Inc. ("Imago") (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs), reported that Hugh Young Rienhoff, Jr., M.D., Imago’s Chief Executive Officer, will participate in three upcoming investor conferences (Press release, Imago BioSciences, MAY 16, 2022, View Source [SID1234614665]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the events are as follows:

HC Wainwright Global Investment Conference. Dr. Rienhoff will participate in a virtual presentation that will be available on demand beginning on Tuesday, May 24, 2022 at 7:00 am ET.

Cowen Oncology Innovation Summit. Dr. Rienhoff will present in an analyst led fireside chat on Thursday, June 2, 2022 at 3:00 pm ET.

Jefferies Healthcare Conference. Dr. Rienhoff will present on Wednesday, June 8, 2022 at 9:30 am ET.

Interested parties can access the live webcasts for these conferences from the Investor Relations section of the company’s website at www.imagobio.com. The webcast replays will be available after the conclusion of each conference.